Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Verified site
Frankfurt, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effects of a new treatment for Rheumatoid Arthritis, a condition that causes pain and swelling in the joints. The treatment being tested is a medication called LY3871801, which is taken in the form of a tablet. The study will compare the effects of LY3871801 to a placebo, which looks like the medication but does not contain the active ingredient.
The purpose of the study is to evaluate how well LY3871801 works in reducing the symptoms of rheumatoid arthritis. Participants in the study will be randomly assigned to receive either LY3871801 or a placebo. The study is designed to be "double-blind," meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment.
The study will take place over a period of up to 24 weeks. During this time, participants will have regular check-ups to monitor their health and the effects of the treatment. The main goal is to see if LY3871801 can help reduce the activity of the disease, as measured by specific health indicators. Participants will be closely monitored to ensure their safety throughout the study.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
3 criteria
10 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Frankfurt, Germany
Paris, France
Encs, Hungary
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
LY3871801 is a new medication being tested to see if it can help people with rheumatoid arthritis, which is a condition that causes pain and swelling in the joints. The study is looking at how well this medication works in reducing the symptoms of rheumatoid arthritis compared to not taking the medication. The goal is to see if people feel better and have less joint pain and swelling when they take LY3871801. This medication is still being studied, so it is not yet available for general use. The trial is designed to find out if LY3871801 can be a safe and effective treatment option for people with this condition.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.